DE60041280D1 - Chimäre mensch-rinder respiratory syncytial virus vakzinen - Google Patents

Chimäre mensch-rinder respiratory syncytial virus vakzinen

Info

Publication number
DE60041280D1
DE60041280D1 DE60041280T DE60041280T DE60041280D1 DE 60041280 D1 DE60041280 D1 DE 60041280D1 DE 60041280 T DE60041280 T DE 60041280T DE 60041280 T DE60041280 T DE 60041280T DE 60041280 D1 DE60041280 D1 DE 60041280D1
Authority
DE
Germany
Prior art keywords
rsv
genome
human
chimeric
bovine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041280T
Other languages
English (en)
Inventor
Ursula Buchholz
Peter L Collins
Brian R Murphy
Stephen S Whitehead
Christine D Krempl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60041280D1 publication Critical patent/DE60041280D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60041280T 1999-07-09 2000-06-23 Chimäre mensch-rinder respiratory syncytial virus vakzinen Expired - Lifetime DE60041280D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313299P 1999-07-09 1999-07-09
PCT/US2000/017755 WO2001004335A2 (en) 1999-07-09 2000-06-23 Human-bovine chimeric respiratory syncytial virus vaccines

Publications (1)

Publication Number Publication Date
DE60041280D1 true DE60041280D1 (de) 2009-02-12

Family

ID=22502738

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041280T Expired - Lifetime DE60041280D1 (de) 1999-07-09 2000-06-23 Chimäre mensch-rinder respiratory syncytial virus vakzinen

Country Status (13)

Country Link
US (2) US7829102B2 (de)
EP (1) EP1287152B1 (de)
JP (1) JP2003530073A (de)
KR (1) KR100905450B1 (de)
CN (2) CN100354425C (de)
AT (1) ATE419369T1 (de)
AU (2) AU784216B2 (de)
BR (1) BR0013195A (de)
CA (1) CA2378552A1 (de)
DE (1) DE60041280D1 (de)
IL (2) IL147447A0 (de)
MX (1) MXPA02000220A (de)
WO (1) WO2001004335A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
MXPA02000490A (es) * 1999-07-13 2004-09-27 Us Gov Health & Human Serv Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
JP4549188B2 (ja) 2002-09-18 2010-09-22 アメリカ合衆国 組換えヒト２型パラインフルエンザウイルス（ＨＰＩＶ２）のｃＤＮＡからの回収（ｒｅｃｏｖｅｒｙ）、並びにＰＩＶおよび他のヒト病原体に対する免疫応答を誘発する免疫原性組成物における、そしてベクターとしての組換えＨＰＩＶ２の使用
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
EP1633860A2 (de) 2003-06-09 2006-03-15 Wyeth VERBESSERTES VERFAHREN ZUR GEWINNUNG NICHTSEGMENTIERTER NEGATIV-STRANG-RNA-VIREN AUS cDNA
US7588770B2 (en) 2003-12-10 2009-09-15 The Uab Research Foundation Recombinant viruses of the paramyxoviridae family with heterologous envelope glycoproteins
EP2471936A3 (de) * 2005-11-24 2013-04-24 The Research Foundation for Microbial Diseases of Osaka University Rekombinanter polyvalenter Impfstoff
EP2217699A4 (de) * 2007-10-22 2012-11-28 Univ Rochester Respiratorisches-syncytial-virus-impfstoff auf der grundlage chimärer papillomavirus-ähnlicher partikel oder capsomeren
EP2313428A2 (de) * 2008-07-01 2011-04-27 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinante human parainfluenza type 1-viren (hpiv1s), die mutationen im c-protein enthalten oder bei denen das c-protein deletiert ist, sind in westlichen grün meerkatzen und in mit cilien versehenen epithelzellen der menschlichen luftwege abgeschwächt und stellen potentielle impfstoffkandidaten für hpiv1 dar
US9011876B2 (en) 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
GB201019240D0 (en) * 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
CN102210859B (zh) * 2011-05-31 2012-11-21 昆明理工大学 一种结核分枝杆菌esat-6-f2融合蛋白亚单位疫苗及其制备方法
US9624475B2 (en) 2012-04-13 2017-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically stable live attenuated respiratory syncytial virus vaccine and its production
JP2014236748A (ja) * 2014-08-26 2014-12-18 一般財団法人阪大微生物病研究会 組換え多価ワクチン
JP7020917B2 (ja) 2015-01-20 2022-02-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ キメラｒｓｖ／ｂｐｉｖ３ ｆタンパクを発現する組換えヒト／ウシパラインフルエンザウイルス３（ｂ／ｈｐｉｖ３）およびその使用
CN110506060B (zh) * 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
TW202012629A (zh) * 2018-04-23 2020-04-01 美國衛生與公眾服務部 嵌合載體
CN112969786A (zh) * 2018-10-12 2021-06-15 Sk生物科学株式会社 重组呼吸道合胞病毒活疫苗株及其制备方法
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
WO2023183700A2 (en) * 2022-03-22 2023-09-28 Mayo Foundation For Medical Education And Research Morreton viruses and methods of use
CN116676275B (zh) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A基因型嵌合腮腺炎病毒株和制备方法及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AU3660893A (en) 1993-01-29 1994-08-15 Med Immune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0702085B2 (de) 1994-07-18 2010-01-13 Conzelmann, Karl-Klaus, Prof. Dr. Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strang-RNS-Virus
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
DK0780475T4 (da) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
CN1285608C (zh) 1995-09-22 2006-11-22 康诺特实验室有限公司 副流感病毒糖蛋白和疫苗
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US5869036A (en) 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
JP4413999B2 (ja) * 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
EP1012244B1 (de) 1997-07-11 2007-05-09 Yale University Rhabdovirus mit gentechnisch veränderter hülle
AU1297299A (en) * 1997-11-10 1999-05-31 University Of Maryland Production of novel bovine respiratory syncytial viruses from cdnas
IL145797A0 (en) 1999-04-13 2002-07-25 Government Of The Us Dept Of H Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
CN100491530C (zh) 1999-04-13 2009-05-27 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒嵌合呼吸道合胞病毒疫苗
AU5918100A (en) 1999-07-09 2001-01-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
MXPA02000490A (es) 1999-07-13 2004-09-27 Us Gov Health & Human Serv Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
DE60136811D1 (de) * 2000-06-23 2009-01-15 Us Gov Health & Human Serv Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren

Also Published As

Publication number Publication date
JP2003530073A (ja) 2003-10-14
WO2001004335A3 (en) 2002-12-19
CN100354425C (zh) 2007-12-12
US20060057158A1 (en) 2006-03-16
KR20020092343A (ko) 2002-12-11
CA2378552A1 (en) 2001-01-18
AU2006202170B2 (en) 2009-10-08
IL147447A0 (en) 2002-08-14
EP1287152A2 (de) 2003-03-05
CN101260386A (zh) 2008-09-10
BR0013195A (pt) 2002-07-23
AU5641500A (en) 2001-01-30
AU2006202170A1 (en) 2006-06-15
WO2001004335A8 (en) 2003-02-06
WO2001004335A2 (en) 2001-01-18
US7842798B2 (en) 2010-11-30
US7829102B2 (en) 2010-11-09
ATE419369T1 (de) 2009-01-15
KR100905450B1 (ko) 2009-07-02
AU784216B2 (en) 2006-02-23
US20070184069A1 (en) 2007-08-09
IL147447A (en) 2010-05-31
EP1287152B1 (de) 2008-12-31
CN1402792A (zh) 2003-03-12
MXPA02000220A (es) 2005-08-16

Similar Documents

Publication Publication Date Title
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
Lu et al. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
DE3878468D1 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
DE69739689D1 (de) Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
WO2002087494A3 (en) Novel vaccine
BR0011160A (pt) Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonados
CA2399172A1 (en) Cold-adapted equine influenza viruses
DE60136811D1 (de) Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren
Park et al. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
Oxburgh Studies of the evolution of the haemagglutinin protein of equine influenza virus H3N8.
BR0105530A (pt) Vìrus da parainfluenza, métodos para estimular o sistema imune de um paciente para induzir proteção contra o vìrus da parainfluenza e para produzir uma partìcula de vìrus da parainfluenza, método de imunização sequencial para estimular o sistema imune de um paciente a induzir proteção contra patógenos múltiplos, composição imunogênica para evocar uma resposta imune contra o virus da parainfluenza, polinucleotìdeo isolado e vetor de expressão
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition